{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-122774","form_type":"8-K","ticker":"MAZE","cik":"0001842295","company_name":"Maze Therapeutics, Inc.","filed_at":"2026-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.500178+00:00","generated_at":"2026-05-15T09:03:44.540428+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Maze Q4 net loss $34.6M; MZE829 Phase 2 35.6% uACR drop; Neil Kumar joins board","bullets":["Net loss $34.6M in Q4, $131.1M for FY2025; cash $360M provides runway into 2028.","MZE829 Phase 2 HORIZON: mean uACR reduction 35.6% at week 12; 50% patients >30% reduction.","FSGS subgroup 61.8% mean uACR reduction; non-diabetic AMKD 48.6%; well-tolerated, no serious AEs.","Neil Kumar (BridgeBio CEO) appointed to board effective March 27, 2026; receives option grant.","Plans to advance MZE829 to pivotal program; MZE782 Phase 2 trials in PKU and CKD expected in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-122774","json":"https://secwatch.observer/filing/0001193125-26-122774.json","markdown":"https://secwatch.observer/filing/0001193125-26-122774.md","text":"https://secwatch.observer/filing/0001193125-26-122774.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842295/000119312526122774/0001193125-26-122774-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842295/000119312526122774/maze-20260324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:03:44.540428+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e2cadfb8790999fcf8ad499f2de4a2b3ea5112cd","claim":"Maze Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2025.","evidence_excerpt":"On March 25, 2026, Maze Therapeutics Inc. (the “Company”) issued a press release reporting its financial results for the fourth quarter and year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1842295/000119312526122774/0001193125-26-122774-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}